Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behçet's disease: a 2-year follow-up

Gen Hosp Psychiatry. 2013 Mar-Apr;35(2):213.e9-11. doi: 10.1016/j.genhosppsych.2012.06.007. Epub 2012 Jul 21.

Abstract

Behçet's disease (BD) is a recurrent inflammatory disorder involving multisystems of the body. Neuropsychiatric symptoms, like psychosis and depression, often occur in BD, but the safety and efficacy of combined clozapine-azathioprine treatment have never been assessed. We here report on a 37-year-old man with BD and treatment-resistant schizophrenia who obtained an improvement following the introduction of clozapine in addition to azathioprine, without developing agranulocytosis or other severe adverse side effects during a 2-year follow-up.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Azathioprine / adverse effects*
  • Behcet Syndrome / drug therapy*
  • Clozapine / adverse effects*
  • Drug Therapy, Combination / adverse effects
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Schizophrenia / drug therapy
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Immunosuppressive Agents
  • Clozapine
  • Azathioprine